In a phase II study with a double-blind, placebo-controlled design, involving 104 patients with mild-to-moderate AD, the topical LXR-β agonist VTP-38543 (Figure 3b) was administered twice daily for 28 days at varying concentrations (0.05%, 0.15%, and 1.0%). Here, NR1H2 is linked to Alzheimer disease.